|
Schering-Plough Submits Supplemental NDA for Use of REBETRON(TM) Combination
Therapy in Treatment-Naive Hepatitis C Patients
MADISON, N.J., June 16 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP)
today announced that it has submitted a supplemental New Drug Application (NDA)
to the U.S. Food and Drug Administration (FDA) seeking marketing approval for
REBETRON(TM) Combination Therapy containing REBETOL(R) (ribavirin, USP) Capsules
and INTRON(R) A (interferon alfa-2b, recombinant) Injection for the treatment
of chronic Hepatitis C in patients with compensated liver disease previously
untreated with alpha interferon therapy (treatment-nanve patients). The company
has requested priority review status for the supplemental NDA.
The FDA on June 3 granted marketing approval for REBETRON combination therapy
for the treatment of chronic Hepatitis C in patients who have relapsed following
alpha interferon therapy. Schering-Plough has submitted a Marketing Authorization
Application for the combination therapy to the European Agency for the Evaluation
of Medicinal Products (EMEA) for the treatment of relapse Hepatitis C patients.
An identical application has been submitted to the EMEA under which oral ribavirin
capsules, if approved, are planned to be marketed by ICN Pharmaceuticals under
the brand name VIRAZOLE(R).
REBETOL is an oral formulation of ribavirin, a synthetic nucleoside analog
with broad-spectrum antiviral activity. Schering-Plough has exclusive rights
to market oral ribavirin for Hepatitis C in all major world markets through
a licensing agreement with ICN Pharmaceuticals, Inc. (NYSE: ICN) of Costa Mesa,
Calif., except in the European Union (EU), where both companies have the right
to market oral ribavirin for Hepatitis C.
INTRON A is a recombinant version of naturally occurring alpha interferon,
which has been shown to exert both antiviral and immunomodulatory effects. Schering-Plough
markets INTRON A, the world's largest-selling alpha interferon, for 16 major
antiviral and anticancer indications worldwide.
Some 4 million Americans are chronically infected with the Hepatitis C virus,
according to the Centers for Disease Control and Prevention (CDCP). The CDCP
has estimated that 20-50 percent of chronically infected Hepatitis C patients
will develop liver cirrhosis, and 20-30 percent of those will go on to develop
liver cancer or liver failure requiring liver transplant. Hepatitis C infection
contributes to the deaths of 8,000 to 10,000 Americans each year. This toll
is expected to triple by the year 2010 and exceed the number of annual deaths
due to AIDS, according to the CDCP. The American Liver Foundation has reported
that liver failure due to Hepatitis C infection is the leading cause of liver
transplants in the United States.
Schering-Plough is a research-based company engaged in the discovery, development,
manufacturing and marketing of pharmaceutical and health care products worldwide.
SOURCE Schering-Plough Corporation
Table Of Contents
Hepatitis Central
http://hepatitis-central.com
|